Skip to content

News

Update on $15 Million Increase Request for OCRP Funding

Update on $15 Million Increase Request for OCRP Funding

(April 1, 2019) 156 House Members have joined Reps. DeLauro and Duffy in a call for increased ovarian cancer research funding. Reps. Rosa DeLauro (D-CT) and Sean Duffy (R-WI) – co-chairs of the Congressional Ovarian Cancer Caucus – today delivered a “Dear Colleague” letter to the House Defense Appropriations Subcommittee requesting a $15 million increase in … Continued

Sign up for OCRA’s National Conference at Early Bird ...

Sign up for OCRA’s National Conference at Early Bird Registration Fee

Empower yourself with the latest research updates at OCRA’s National Conference. Register today. It can be overwhelming trying to keep up with what’s new in the ovarian cancer field, and how new discoveries may affect you. At OCRA’s National Conference, you can get a front row seat at expert plenary and breakout sessions, where leaders … Continued

Shop Designer Brands to End Ovarian Cancer

Shop Designer Brands to End Ovarian Cancer

OCRA is now on Shopify and Poshmark Wardrobe need a refresh? Now you can shop high-end, limited quantity designer goods online at deep discounts, all while supporting the fight against ovarian cancer. Browse our exciting collection of shoes, accessories, and apparel for women, men and children, from top brands including Johnny Was, Ramy Brook, Kenneth … Continued

National Comprehensive Cancer Network Updates Guidelines

National Comprehensive Cancer Network Updates Guidelines

(March 26, 2019) The NCCN, or the National Comprehensive Cancer Network, recently updated its clinical guidelines for the treatment of ovarian cancers. The guidelines, a summary of which can be found here, have been updated after several studies were completed and the FDA approved several new drugs. The new guidelines address topics such as PARP … Continued

OCRA Funded Study Aims to Increase Efficacy of PARP Inhibitors

OCRA Funded Study Aims to Increase Efficacy of PARP Inhibitors

(March 20, 2019) The Ovarian Cancer Dream Team, funded in part by OCRA, recently completed a Phase 1b Trial, which combined a PARP inhibitor with an HRR (homologous recombination repair) pathway inhibitor, such as PI3K, in order to increase the efficacy of PARP inhibitors in breast and epithelial ovarian cancers. Phase 1 trials are used … Continued

OCRA Spring Advocacy Day 2019 Actions

OCRA Spring Advocacy Day 2019 Actions

(March 20, 2019) Earlier this month, OCRA united advocates from across the country for Spring Advocacy Day on Capitol Hill. Together, this passionate group of survivors, caregivers and supporters used their collective voice to advocate for increased funding for ovarian cancer research and education. Learn more about our asks for Ovarian Cancer Research Program (OCRP) … Continued

Action Alert: Tell Congress to Increase OCRP Funding

Action Alert: Tell Congress to Increase OCRP Funding

(March 19, 2019) Congress is considering a $15 million increase for OCRP funding. Urge YOUR Representative to sign the letter to help push this funding through. Deadline is March 25th! Tell Congress to Increase OCRP Funding The Ovarian Cancer Research Program (OCRP) is a cutting-edge program housed within the Department of Defense and despite a … Continued

Lymphadenectomy in Ovarian Cancer Patients Can Be Unnecessary

Lymphadenectomy in Ovarian Cancer Patients Can Be Unnecessary

(March 18, 2019) Before the most recent study on the usage of lymphadenectomy, published earlier this month in the New England Journal of Medicine, it was thought that surgically removing clinically negative lymph nodes had a positive effect on the patient’s health. Now, doctors are rethinking that approach. The LION, Lymphadenectomy in Ovarian Neoplasms, trial … Continued

OCRA-Funded Research Indicates that Stem-Like Cells May Be Key to Preventing Recurrence

OCRA-Funded Research Indicates that Stem-Like Cells May Be Key to Preventing Recurrence

(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients. Researchers, including OCRA grantees Illana Chefetz, PhD and Ronald Buckanovich, MD, PhD, identified a new drug, 673A, that finds and destroys stem-like ovarian cancer cells. Stem-like cells are … Continued

Statement from Audra Moran, President and CEO of Ovarian Cancer Research Alliance on the President’s FY2020 Budget

Statement from Audra Moran, President and CEO of Ovarian Cancer Research Alliance on the President’s FY2020 Budget

(March 12, 2019) “The President’s proposed FY2020 budget released by the White House on Monday seeks to cut medical research funding at the National Cancer Institute (NCI) by 15 percent – almost $900 million dollars compared to FY2019 funding. The budget also slashes the Centers for Disease Control’s (CDC) Chronic Disease Program by almost 20 … Continued

Remembering Lori Newcomb

Remembering Lori Newcomb

(March 1, 2019) OCRA mourns the loss of our beloved board member and friend, Lori Newcomb. We are profoundly grateful for her vision and dedication in creating Newk’s Cares along with her loving husband, Chris, to support ovarian cancer research through their family business, Newk’s Eatery. Her unwavering and selfless commitment to help other women … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.